CAJ | 학술논문

目的：评价麻醉诱导前静脉预注苯磺顺阿曲库铵对舒芬太尼诱发咳嗽（ SFIC）的抑制效果。方法200例气管插管全麻患者随机分为2组，每组各100例。对照组静脉注射0．9％NaCl 1 mL，苯磺顺阿曲库铵预处理组注射苯磺顺阿曲库铵0．01 mg? kg－1。2组均于5 min后静脉注射舒芬太尼0．4μg? kg－1，注射时间2s。记录2组患者咳嗽发生次数和时间，并根据咳嗽次数进行严重程度分级。分别于注射0．9％NaCl或苯磺顺阿曲库铵时、注射舒芬太尼时及注射后1，2 min记录患者血压、心率、呼吸、脉搏血氧饱和度及药物不良反应。结果苯磺顺阿曲库铵预处理组SFIC的发生率（11．0％）明显低于对照组（35．0％）（ P＜0．05）；舒芬太尼诱发中度和重度咳嗽4例次（占36．4％），明显少于对照组的25例次（占71．4％）（ P＜0．05）。2组咳嗽发生时间、血压及心率比较，差异无统计学意义。结论苯磺顺阿曲库铵预处理能有效降低SFIC的发生率和强度。
목적：평개마취유도전정맥예주분광순아곡고안대서분태니유발해수（ SFIC）적억제효과。방법200례기관삽관전마환자수궤분위2조，매조각100례。대조조정맥주사0．9％NaCl 1 mL，분광순아곡고안예처리조주사분광순아곡고안0．01 mg? kg－1。2조균우5 min후정맥주사서분태니0．4μg? kg－1，주사시간2s。기록2조환자해수발생차수화시간，병근거해수차수진행엄중정도분급。분별우주사0．9％NaCl혹분광순아곡고안시、주사서분태니시급주사후1，2 min기록환자혈압、심솔、호흡、맥박혈양포화도급약물불량반응。결과분광순아곡고안예처리조SFIC적발생솔（11．0％）명현저우대조조（35．0％）（ P＜0．05）；서분태니유발중도화중도해수4례차（점36．4％），명현소우대조조적25례차（점71．4％）（ P＜0．05）。2조해수발생시간、혈압급심솔비교，차이무통계학의의。결론분광순아곡고안예처리능유효강저SFIC적발생솔화강도。
Objective To observe the effect of intravenous cisatracurium besilate pre -treatment on sufentanyl -induced cough ( SFIC ) . Methods Two hundred patients scheduled for elective surgery were ran-domly divided into two groups.Patients in treatment group received intra-venous cisatracurium besilate 0.01 mg? kg-1 and those in control group were given 0.9%NaCl 1 mL through the left median cubital veins.Five minutes later, the patients were injected with sufentanyl 0.4μg? kg-1 in two seconds.The timing and numbers of coughing were recorded and classified according to numbers.The data of blood pressure, heart rate, respiration, SpO2 and adverse reactions of patients were recorded at the moment of injection of 0.9%NaCl or cisatracurium besilate, the injection of sufentanyl and one and two minutes after injections.Results The in-cidence of cough was 11.0%( 11/100 ) in treatment group and 35%(35/100) in control group (P<0.05).The incidence of moderate and severe cough was significantly higher in the control group ( 71.4%, 25/35) than in treatment group (36.4%,4/11)(P<0.05).There was no significant difference between two groups on the timing of cough, blood pressure and heart rate. Conclusion Cisatracurium besilate pre-treatment can effectively reduce the incidence and severity of SFIC.